Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus called SARS-CoV-2. As of January 25, 2021, there have been over 99.4 million cases and 2.13 million deaths worldwide.
The purpose of our project is to achieve the following:
- Among participants reporting COVID-like illnesses, calculate the incidence of molecular test-confirmed SARS-CoV-2 infections and report the incidence among the general population, health care workers, minorities, county location, COVID-19 contacts, age groups, and use of PPE by health workers
- To calculate the baseline seroprevalence and zero-incidence of symptomatic and asymptomatic SARS-CoV-2 infection among the general population, health care workers, minorities, county, COVID-19 contacts, age groups, and use of PPE by health workers
- To calculate the incidence of sequelae including the case fatality ratio
- To evaluate long-term sequelae of infection, the durability of immunity, re-emergence of transmission after social distancing measures are relaxed and related questions of public health importance for our nation
Vysnova Partners collaborates with six institutions such as Tulane, Wake Forest, Atrium Health, MedStar, University of Mississippi, and the University of Maryland. We oversee contract management, serology supply chain, internal and external study communications, the study call center, and we facilitate the overall research process
The Vysnova Impact:
Vysnova manages all study decisions and optimizes research management that leads to syndromic and serologic results for the CDC (Centers for Disease Control and Prevention). In the future, Vysnova plans to expand participation across all sites and continue to collect data to better understand the impact of COVID-19 nationally.